VIB researchers reveal new therapeutic avenue in the fight against cancer

July 04, 2016

Targeting NEAT1 and 'paraspeckles' increases chemosensitivity of cancer cells

A team of researchers led by professor Jean-Christophe Marine (VIB-KU Leuven) has identified NEAT1, a non-coding RNA, as a potential therapeutic target in the fight against cancer. In collaboration with the renowned Cédric Blanpain lab (ULB), VIB researchers have shown that NEAT1 plays an important role in the survival of highly dividing cells -- and in particular of cancer cells. These findings can help develop new drugs that target NEAT1, in order to kill cancer cells more effectively.

As a non-coding RNA, NEAT1 is not translated into a protein. It does however contribute to the formation of so-called 'paraspeckles', subnuclear particles that can be found in the cell nuclei of cancer cells. The function of these particles has remained obscure. Although highly conserved through evolution, NEAT1 appears to be dispensable for normal embryonic development and adult life as mice lacking NEAT1 are viable and healthy.

Guarding the genome

PhD student Carmen Adriaens (VIB-KU Leuven): "In our study, we have found that the expression of NEAT1 in the cell nucleus is regulated by p53. This protein plays an important role in protecting people against cancer and is known as 'the guardian of the genome'. When a cell is stressed or damaged, p53 will upregulate the expression of NEAT1, which leads to the formation of paraspeckles. This has two possible outcomes: the cell can either go into transient cell cycle arrest, giving it time to deal with the stress and repair the damage before continuing cell division. If the stress or damage is too high, however, p53 will instruct the cell to commit suicide and die."

The hijacking of NEAT1

A key observation made by the VIB researchers is that NEAT1/paraspeckles are required for the survival of highly dividing cancer initiating cells and that mice lacking NEAT1 are protected from developing skin cancer. This means that cancer cells can 'hijack' the survival principle of NEAT1 for their own good.

Prof. Jean-Christophe Marine (VIB-KU Leuven): "We expected NEAT1 to be a tumor suppressor, since it is regulated by p53. Instead, it turned out that NEAT1 helps cancer cells in growing opportunistically. They use the survival mechanisms put in place by NEAT1 to survive standard chemotherapeutics. Our research shows that cancer cells die more effectively after removing NEAT1/paraspeckles from the cell nucleus. In other words: the loss of NEAT1 leads to increased chemosensitivity and cell death. Therefore, our findings can help develop new drugs targeting NEAT1 in order to kill cancer cells more effectively."

Next steps

Since normal cells do not rely on NEAT1/paraspeckles, these nuclear bodies may be promising therapeutic targets. The researchers will now try to get a better understanding of how exactly NEAT1 confers its survival functions to cells. The ultimate goal of the Jean-Christophe Marine Lab is to find out how this knowledge can be harnessed to help cure cancer.
-end-
Publication

p53 induces NEAT1 paraspeckles to modulate replication stress response and chemosensitivity, Adriaens, Standaert, et al., Nature Medicine 2016 DOI: 10.1038/nm.4135

Questions

As this research may raise questions, we want to ask you to list the e-mail address that the VIB has made available for questions in your report or article. Everyone can contact us with questions about this research and other medical research: patients@vib.be

VIB (the Flanders Institute for Biotechnology)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.